Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.

Clinical therapeutics - 1 Mar 2010

Tol Jolien, Punt Cornelis J A

Abstract excerpt

BACKGROUND: Two groups of agents targeting either the vascular endothelial growth factor (VEGF) receptor or the epidermal growth factor receptor (EGFR) have been added to the therapeutic arsenal against metastatic colorectal cancer (mCRC). Currently available agents in these groups are the anti-VEGF antibody bevacizumab and the anti-EGFR antibodies cetuximab and panitumumab. OBJECTIVES: This article reviews the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Drug Delivery Systems
Share to Neoplasm Metastasis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to Randomized Controlled Trials as Topic

Share to ras Proteins

Share to Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 20399983
DOI: 10.1016/j.clinthera.2010.03.012

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.PMID 20399983Read ↗

Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.Semantic proximity Read ↗

The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.Semantic proximity Read ↗

Antiepidermal growth factor receptor monoclonal antibody improves survival outcomes in the treatment of patients with metastatic colorectal cancer.Semantic proximity Read ↗

Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies.Semantic proximity Read ↗

Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study.Semantic proximity Read ↗

Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.Semantic proximity Read ↗

The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.Semantic proximity Read ↗

[Anti-EGFR antibody therapy for colorectal cancer].Semantic proximity Read ↗

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.Semantic proximity Read ↗

Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations.Semantic proximity Read ↗

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.Semantic proximity Read ↗

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.